Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
SPRUCE BIOSCIENCES, INC. (SPRB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Charlton Ralph William III (Chief Medical Officer) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 12,378 shares
@ $0.9775, valued at
$12.1k
|
|
| 07/05/2023 |
4
| Szwarcberg Javier B. (CEO) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 20,000 shares
@ $0.9775, valued at
$19.6k
|
|
| 07/05/2023 |
4
| Gharib Samir M. (President & CFO) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 10,484 shares
@ $0.9775, valued at
$10.2k
Paid exercise price by delivering 25,936 shares
@ $2.15, valued at
$55.8k
Exercised 75,000 restricted stock units
@ $0 |
|
| 05/30/2023 |
SC 13D/A
| RiverVest Venture Fund III, L.P. reports a 8.6% stake in SPRUCE BIOSCIENCES, INC. |
| 05/26/2023 |
4
| Ways Kirk (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 30,000 options to buy
@ $2.26, valued at
$67.8k
|
|
| 05/26/2023 |
4
| SPIEGELMAN DANIEL K (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 30,000 options to buy
@ $2.26, valued at
$67.8k
|
|
| 05/26/2023 |
4
| SIMPSON CAMILLA V (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 30,000 options to buy
@ $2.26, valued at
$67.8k
|
|
| 05/26/2023 |
4
| O'Donnell Niall (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 30,000 options to buy
@ $2.26, valued at
$67.8k
|
|
| 05/26/2023 |
4
| Muralidhar Bali (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 30,000 options to buy
@ $2.26, valued at
$67.8k
|
|
| 05/26/2023 |
4
| GREY MICHAEL G (Executive Chairman) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 30,000 options to buy
@ $2.26, valued at
$67.8k
|
|
| 05/26/2023 |
4
| Aynechi Tiba (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 30,000 options to buy
@ $2.26, valued at
$67.8k
|
|
| 05/26/2023 |
4
| Barretto-Ko Percival (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Granted 60,000 options to buy
@ $2.26, valued at
$135.6k
|
|
| 05/26/2023 |
3
| Barretto-Ko Percival (Director) has filed a Form 3 on SPRUCE BIOSCIENCES, INC. |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/16/2023 |
4
| O'Donnell Niall (Director) has filed a Form 4 on SPRUCE BIOSCIENCES, INC.|
Txns:
| Bought 630,400 shares
@ $3.17, valued at
$2M
Bought 472,800 warrants
@ $3.96, valued at
$1.9M
|
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/16/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/28/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/27/2023 |
SC 13G
| 5AM Opportunities II, L.P. reports a 10% stake in Spruce Biosciences, Inc. |
| 02/23/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 9.2% stake in Spruce Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 6.9% stake in Spruce Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SPRUCE BIOSCIENCES, INC. Warrant Shares: [_______] Issue Date: [____], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK certifies that, for value received, [_____________] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until 5:00 p.m. on [___], 2028 but not thereafter, to subscribe for and purchase from Spruce Biosciences, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following ter...",
"COMMON STOCK PURCHASE WARRANT SPRUCE BIOSCIENCES, INC. Warrant Shares: [_______] Issue Date: [____], 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_____________] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until 5:00 p.m. on [___], 2028 but not thereafter, to subscribe for and purchase from Spruce Biosciences, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicat...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement , dated as of February 8, 2023, is made by and among Spruce Biosciences, Inc., a Delaware corporation , and the Purchasers listed on hereto, together with their permitted transferees . Recitals A. The Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act and/or Rule 506 of Regulation D as promulgated by the SEC under the Securities Act. B. The Purchasers, severally, and not jointly, desire to purchase from the Company, and the Company desires to sell to the Purchasers, upon the terms and conditions stated in this Agreement, shares of the Company’s common stock, par value $0.0001 per share , to certain Purch..." |
|
|
|
|